ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study.

Jinhui Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.